Last reviewed · How we verify
Early Breast Cancer Hormone Receptor Positive and Postmenopausal
Approved treatments
- Femara · M.D. Anderson Cancer Center
- Femara · Novartis AG
Letrozole reduces estrogen levels by inhibiting the aromatase enzyme, which converts androgens to estrogens.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Early Breast Cancer Hormone Receptor Positive and Postmenopausal patent landscape — cliff calendar, originator estates, attackable patents
- Early Breast Cancer Hormone Receptor Positive and Postmenopausal treatment landscape brief
- Early Breast Cancer Hormone Receptor Positive and Postmenopausal treatment updates RSS
Frequently asked questions about Early Breast Cancer Hormone Receptor Positive and Postmenopausal
What drugs treat Early Breast Cancer Hormone Receptor Positive and Postmenopausal?
Tracked treatments include Femara.
What is the treatment for Early Breast Cancer Hormone Receptor Positive and Postmenopausal?
Standard treatment for Early Breast Cancer Hormone Receptor Positive and Postmenopausal includes Femara. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Early Breast Cancer Hormone Receptor Positive and Postmenopausal patent cliff · Early Breast Cancer Hormone Receptor Positive and Postmenopausal CI report
- Treatment: Femara · M.D. Anderson Cancer Center
- Treatment: Femara · Novartis AG
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing